StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd (OTCMKTS:GNWSF) is a biotechnology company focused on developing and commercializing non-invasive diagnostic tests for the early detection of cancer and other chronic diseases. The company’s core technology employs advanced epigenetic and molecular biomarker analysis to identify disease signals in blood samples at asymptomatic stages. By integrating next-generation sequencing and machine learning algorithms, StageZero aims to enable clinicians to diagnose conditions earlier and improve patient outcomes.

StageZero’s flagship offering, CancerDetect, is a multi-cancer early detection assay designed to screen for several types of cancer in a single blood draw. This platform is supported by an expanding patent portfolio and validation studies conducted in collaboration with academic research centers and clinical laboratories. In addition to CancerDetect, the company provides contract research services—including custom assay development, biomarker discovery and clinical trial support—to pharmaceutical and biotechnology partners pursuing precision medicine solutions.

Headquartered in Canada, StageZero operates CLIA-certified laboratories to process high-volume clinical samples and adheres to stringent quality and regulatory standards. The company has initiated pilot programs in North America and Asia and is working toward broader market access in Europe, where demand for early detection diagnostics continues to grow. These strategic expansions are designed to accelerate clinical adoption and facilitate reimbursement discussions with healthcare systems and payers.

Supported by a leadership team with deep expertise in genomics, diagnostics and healthcare commercialization, StageZero Life Sciences is advancing its product pipeline to address unmet needs in population health management. The company continues to pursue partnerships with hospitals, research institutions and industry stakeholders to scale its testing platform and extend its reach into new geographies.

Key Stats

• Today's Range: $0.0051 to $0.0051
• 50-Day Range: $0.01 to $0.02
• 52-Week Range: $0.00 to $1.27
• Volume: N/A
• Average Volume: 26,719 shs
• Market Capitalization: $321.27 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNWSF Stock Analysis - Frequently Asked Questions

How have GNWSF shares performed this year?

StageZero Life Sciences' stock was trading at $0.0016 at the beginning of the year. Since then, GNWSF shares have increased by 218.8% and is now trading at $0.0051.

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNWSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: 905-209-2030
• Fax: N/A
• Employees: 80
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.86 million
• Net Margins: -200.26%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -165.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $4.15 million
• Price / Sales: 0.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -0.26

Miscellaneous

• Outstanding Shares: 62,995,000
• Free Float: N/A
• Market Cap: $321.27 thousand
• Optionable: Not Optionable
• Beta: 0.28